“OptumRx will continue to negotiate lower prices through discounts over time, be transparent with our customers, and implement clinical evidence-based guidelines so the right people get appropriate medicines.”

In context

“rice points, we're really trying to work with manufacturers to get to some aligned value-based constructs, getting pricing to a point where it's based on outcomes and adherence levels, all the way to outright risk on utilization levels, and pairing those with therapies and programs that can put less reliance on lifelong adherence requirements like these drugs currently have. We're not there yet. We're optimistic, but we can get there, but clearly price point is a key barrier. Andrew Witty: Brian, thanks so much. And Patrick, maybe from the -- from OptumRx perspective, you could talk a little bit about the broader approaches we take? Patrick Conway: Thank you. As Andrew said, our customers, payers, employers, people we serve are concerned about the prices of GLP-1s as set by manufacturers. OptumRx will continue to negotiate lower prices through discounts over time, be transparent with our customers, and implement clinical evidence-based guidelines so the right people get appropriate medicines. And as you alluded to, Lisa, obesity and cardiometabolic disease is a major public issue -- health issue in the U.S. and across all of [Oxfam] (ph), we are developing and implementing comprehensive solutions of which medicines are only a part of on behalf of our clients and people we serve to drive better health outcomes for all and value to the health system. Andrew Witty: Thanks, Patrick. And Lisa, thanks so much for the question. Next question, please, Jennifer. Operator: Yes, we'll go next to A.J. Rice with [UBS] (ph). Unidentified Analyst: Hi, everybody. Thanks for the question. You know, it's similar to last quarter, the trend in margin and OptumHealth and OptumInsight has been down year-to-year, you know, you've called out change, particularly with OptumInsight, but I wondered if t”